Product
CB-103
4 clinical trials
12 indications
Indication
Breast CancerIndication
Colorectal CancerIndication
Adenoid Cystic CarcinomaIndication
Non-Hodgkin LymphomaIndication
Glomus TumorIndication
malignantIndication
Hepatocellular CarcinomaIndication
OsteosarcomaIndication
T-ALLIndication
Metastatic Adenoid Cystic CarcinomaIndication
LeukemiaIndication
LymphoblasticClinical trial
A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study With Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients With Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling PathwayStatus: Terminated, Estimated PCD: 2022-11-11
Clinical trial
A Phase 1/2 Study of CB-103 (Oral Pan-NOTCH Inhibitor) With Abemaciclib or Lenvatinib in Combination in Patients With NOTCH Activated Adenoid Cystic Carcinoma (CALCulus)Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
CB-103 Plus NSAI In Luminal Advanced Breast Cancer: CAILA StudyStatus: Terminated, Estimated PCD: 2021-09-02
Clinical trial
A Phase II Study to Evaluate Safety and Efficacy of CB-103 in Combination With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)Status: Recruiting, Estimated PCD: 2026-07-01